Trial Profile
A Randomized, Double-Blind, Placebo Controlled, Multicenter 2a Study to Assess Safety, Daily Respiratory Symptoms, PK, and Biomarker Variations After Administration of Either YPL-001, or Placebo in Patients With Moderate-to-Severe COPD.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 17 Jul 2023
Price :
$35
*
At a glance
- Drugs YPL 001 (Primary)
- Indications Chronic obstructive pulmonary disease
- Focus Adverse reactions; Proof of concept
- Sponsors Yungjin Pharm Co
- 01 Sep 2018 Results published in the Clinical Pharmacology in Drug Development
- 23 May 2018 Results presented at the 114th International Conference of the American Thoracic Society
- 23 May 2018 Status changed to completed as per results presented at the 114th International Conference of the American Thoracic Society